rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
3
|
pubmed:dateCreated |
2009-5-5
|
pubmed:abstractText |
Drug company-sponsored patient assistance programs (PAPs) provide access to brand-name medications at little or no cost and have been advocated as a safety net for inadequately insured patients. Yet little is known about these programs. We surveyed drug company-sponsored PAPs and found much variability in their structures and application processes. Most cover one or two drugs. Only 4 percent disclosed how many patients they had directly helped, and half would not disclose their income eligibility criteria. A better understanding of PAPs might clarify their role in improving access to medications, the adequacy of existing public programs, and their impact on cost-effective medication use.
|
pubmed:grant |
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19414893-11242426,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19414893-11903757,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19414893-11926851,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19414893-15061432,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19414893-15462253,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19414893-15790800,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19414893-15901589,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19414893-16738271,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19414893-16790577,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19414893-16881945,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19414893-17118944,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19414893-17211028,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19414893-17609491,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19414893-17874869,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19414893-17944892,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19414893-18285564,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19414893-18362819
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1544-5208
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:volume |
28
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
827-34
|
pubmed:dateRevised |
2010-12-3
|
pubmed:meshHeading |
pubmed-meshheading:19414893-Beneficence,
pubmed-meshheading:19414893-Cost-Benefit Analysis,
pubmed-meshheading:19414893-Disclosure,
pubmed-meshheading:19414893-Drug Costs,
pubmed-meshheading:19414893-Drug Industry,
pubmed-meshheading:19414893-Eligibility Determination,
pubmed-meshheading:19414893-Financing, Organized,
pubmed-meshheading:19414893-Financing, Personal,
pubmed-meshheading:19414893-Health Services Accessibility,
pubmed-meshheading:19414893-Humans,
pubmed-meshheading:19414893-Income,
pubmed-meshheading:19414893-Medical Assistance,
pubmed-meshheading:19414893-Mental Disorders,
pubmed-meshheading:19414893-Psychotropic Drugs,
pubmed-meshheading:19414893-Uncompensated Care,
pubmed-meshheading:19414893-United States
|
pubmed:articleTitle |
Drug company-sponsored patient assistance programs: a viable safety net?
|
pubmed:affiliation |
Brigham and Women's Hospital (BWH), Division of Pharmacoepidemiology and Pharmacoeconomics, in Boston, Massachusetts, USA. nchoudhry@partners.org
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|